首页> 外文OA文献 >A Novel Disease-Modifying Antirheumatic Drug, Iguratimod, Ameliorates Murine Arthritis by Blocking IL-17 Signaling, Distinct from Methotrexate and Leflunomide

【2h】

A Novel Disease-Modifying Antirheumatic Drug, Iguratimod, Ameliorates Murine Arthritis by Blocking IL-17 Signaling, Distinct from Methotrexate and Leflunomide

机译：一种新型疾病改性的抗抗肠药物Iguratimod通过阻断IL-17信号传导而改善小鼠关节炎，不同于甲氨蝶呤和leflunomide

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Qiong Luo; Yang Sun; Wen Liu; Cheng Qian; Biao Jin; Feifei Tao; Yanhong Gu; Xingxin Wu; Yan Shen; Qiang Xu;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A Novel Disease-Modifying Antirheumatic Drug, Iguratimod, Ameliorates Murine Arthritis by Blocking IL-17 Signaling, Distinct from Methotrexate and Leflunomide [J] . Qiong Luo, Yang Sun, Wen Liu, The journal of immunology . 2013,第10期

机译：新型抗风湿病药物伊古拉莫德通过阻断与甲氨蝶呤和来氟米特不同的IL-17信号传导，改善小鼠关节炎
2. A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide [J] . LuoQ., SunY., LiuW., The Journal of Immunology: Official Journal of the American Association of Immunologists . 2013,第10期

机译：与甲氨蝶呤和来氟米特不同，一种新型的能缓解疾病的抗风湿药iguratimod通过阻断IL-17信号传导改善鼠关节炎。
3. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: Results of a 1-year follow-up study from the CERERRA collaboration [J] . ChatzidionysiouK., LieE., NasonovE., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2012,第3期

机译：甲氨蝶呤和来氟米特联合抗病抗风湿药的联合疗法在利妥昔单抗治疗的类风湿关节炎患者中的有效性：CERERRA合作进行的为期1年的随访研究结果
4. Comparative effectiveness of treatment with the first TNF antagonist in monotherapy the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis [O] . Blanca Hernández-Cruz, Esther Márquez-Saavedra, Rafael Caliz-Caliz, 2016

机译：在类风湿性关节炎患者中第一种TNF拮抗剂在单一疗法第一种TNF拮抗剂加一种常规的合成疾病缓解性抗风湿药和第一种TNF拮抗剂加两种或多种常规合成的疾病缓解性风湿性药物治疗中的比较疗效
5. Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study [O] . Daihua Deng, Jun Zhou, Min Li, 2020

机译：Leflunomide单疗法与常规综合性疾病改性抗风药物用于类风湿性关节炎的组合治疗：回顾性研究

A Novel Disease-Modifying Antirheumatic Drug, Iguratimod, Ameliorates Murine Arthritis by Blocking IL-17 Signaling, Distinct from Methotrexate and Leflunomide

著录项

相似文献

相关主题

期刊订阅